The September 30, 2020 quarterly, and December 31, 2021 full year earnings estimates for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 58.35) have...
Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 58.13) 2021 forecasted earnings estimate for the year ending December 31, 2021 has been increased. The...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
The June 30, 2020 quarterly, and December 31, 2021 full year earnings estimates for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 56.10) have been...
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 08/06/2020 10-Q |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| Chief Financial Officer | Charles A. Reinhart |
| Vice President-Research & Development | Vladimir Kharitonov |
| Chief Technology Officer | Charles Anthony Laranjeira |
| Price Open | $58.14 |
| Previous Close | $58.35 |
| 52 Week Range | $27.46 - 59.93 |
| Market Capitalization | $2.5 B |
| Shares Outstanding | 42.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 11/05/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | $0.16 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | -2.47% |
| Return on Equity | -2.76% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
